Featured Publications
Ready, willing and able: a model to explain successful use of feedback
Garino A. Ready, willing and able: a model to explain successful use of feedback. Advances In Health Sciences Education 2019, 25: 337-361. PMID: 31598884, DOI: 10.1007/s10459-019-09924-2.Peer-Reviewed Original Research
2023
Barriers to Research: A National Survey of Physician Assistant Faculty
Lolar S, Welch R, Garino A. Barriers to Research: A National Survey of Physician Assistant Faculty. The Journal Of Physician Assistant Education 2023, 34: 20-27. PMID: 36630214, DOI: 10.1097/jpa.0000000000000480.Peer-Reviewed Original Research
2006
Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree
Alexandrescu DT, Garino A, Brown-Balem KA, Wiernik PH. Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree. Leukemia & Lymphoma 2006, 47: 2115-2127. PMID: 17071485, DOI: 10.1080/10428190600724928.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaMean anticipationGeneration of lymphomasDisease-free survivalEnd Results ProgramUS National Cancer InstituteAge of onsetNational Cancer InstituteNHL groupSEER populationSurveillance EpidemiologyResults ProgramMean ageCancer InstituteLymphomaNHLEarly onsetHodgkinUnpublished familiesAgeParent-child pairsRank testChildrenUnreported familiesOnset
2004
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004, 101: 1545-1551. PMID: 15378501, DOI: 10.1002/cncr.20541.Peer-Reviewed Original ResearchConceptsSarcomatoid renal cell carcinomaRenal cell carcinomaCell carcinomaAntitumor activityGemcitabine-based regimensGrade 4 toxicityModest antitumor activitySite of metastasisSite of diseaseCombination of doxorubicinInstitutional review boardStable diseaseMedian durationMedian survivalPartial responseRecurrent diseaseComplete responseActive chemotherapyFactor supportMedian timeDuct carcinomaProspective InvestigationInterleukin-2PatientsGemcitabine